Myocardial Infarction Genes (MI-GENES) Study

Overview

About this study

This study is being done to better understand how genetic information might improve assessment of heart attack risk.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients between the ages of 45-70 years
Patients who have participated in the Mayo Clinic Biobank or a previous research study at Mayo Clinic
Patients who live in Southeast Minnesota

Exclusion Criteria:

Taking statin or other lipid lowering medications
Patients with a history of myocardial infarction, coronary artery disease, or other atherosclerotic medical conditions

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Iftikhar Kullo, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Iftikhar Kullo, M.D.

Closed for enrollment

More information

Publications

Susceptibility variants identified by genome-wide association studies (GWAS) have modest effect sizes. Whether such variants provide incremental information in assessing risk for common 'complex' diseases is unclear. We investigated whether measured and imputed genotypes from a GWAS dataset linked to the electronic medical record alter estimates of coronary heart disease (CHD) risk. Read More on PubMed

Clinical Trials